Porcine Vaccine Market, By Type (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine Influenza, Aujeszky’s Disease (AD), Porcine Circovirus Associated Disease (PCVAD), By End-User (Veterinary Hospitals & Hog Production Farm and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Vaccines are the most effective means of disease prevention in both animals and humans. In veterinary medicines, vaccination is seen as a godsend for sustaining animal welfare by preventing the spread of numerous endemic diseases. Porcine vaccines are used in the clinic to improve pig health and protect them from severe diseases by protecting them from viruses, bacteria, and other pathogens. Porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) are just a few of the diseases that can affect pigs. It also improves overall efficiency in protecting pigs from dangerous illnesses while increasing the yield of high-quality meat for human consumption. Many diseases, such as cholera and foot-and-mouth disease, have been virtually eradicated in North America and Europe thanks to the use of these vaccines. The Global Porcine Vaccine Market accounted for US$ 2.23 billion in 2020 and is estimated to be US$ 4.41 billion by 2030 and is anticipated to register a CAGR of 7.50%.

Rising occurrence of illnesses in swine

One of the primary factors driving the growth of the porcine vaccines market is the rising occurrence of illnesses in swine around the world. Market growth is accelerated by constant market innovation to fulfil customer demand and a rise in government initiatives to fund vaccine development phases. The market is also influenced by the increased focus on providing vaccination services in order to properly use swine vaccinations for managing germs or viruses. Furthermore, technological advancements, population expansion, the increase in the number of generic medicine makers, and population growth all benefit the porcine vaccines industry. Furthermore, in the projection period, special designation from the regulatory body provides profitable chances to market players.

On the other side, the market expansion is projected to be hampered by the high cost of vaccinations. In the forecast period, the market for porcine vaccines is expected to be hampered by strict restrictions.

The global porcine vaccines market report segments the market on the basis of type, disease indication, end-user, and region.

On the basis of Type, the global porcine vaccines market is segmented into Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines. On the basis of Disease Indication, the target market is segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine Influenza, Aujeszky’s Disease (AD), Porcine Circovirus Associated Disease (PCVAD). Based on End-User, the market is segmented into Veterinary Hospitals & Hog Production Farm and Others.

Regional Insights:

On region the global oncology drug market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the highest market share in the worldwide porcine vaccinations market because of its highly structured farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners. Furthermore, export and import permissions among contract manufacturers or distributors, as well as low predicted product costs, are expected to increase the popularity of porcine vaccines in Europe. For example, in 2016, the UK-based Cranswick Foods company launched a project in Punjab to establish a pork processing plant, which would act as a catalyst to accelerate the process of value addition in the animal husbandry sector and boost farm diversification while providing high-quality pork to consumers across the state. The market in Asia Pacific (which includes Vietnam, the Philippines, and other countries) is expected to rise at a considerable CAGR throughout the projected period, owing to high pig meat consumption in these countries, which is fueling market expansion.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Porcine Vaccine Market report based on Type, Disease Indication, End-User and Region.

Global Porcine Vaccine Market, By Region:

• North America
  • • • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the Global Porcine Vaccine Market includes Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale SA, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Zoetis, Inc. and Vitus Animal Health, Inc.

• Bayer AG
  • Vetoquinol S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Ceva Sante Animale SA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Boehringer Ingelheim International GmbH
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Bimeda, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategies
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategies

 “*” marked represents similar segmentation in other categories in the respective section